Global Hodgkin’s Lymphoma Market - 2023-2030

Global Hodgkin’s Lymphoma Market - 2023-2030

The Global Hodgkin’s Lymphoma Market reached US$ 0.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.1 billion by 2030. The global Hodgkin’s lymphoma market is expected to exhibit a CAGR of 9.8% during the forecast period (2023-2030). The increasing technological advancements and the growing investments in novel products are driving up demand for Hodgkin’s lymphoma market trends.

The market for Hodgkin’s lymphomas includes types and therapies that establish the existence of the disease. 15% of all malignancies in young adults worldwide are Hodgkin's lymphoma, which makes up 95% of all HLs. The launch of new treatments and an increase in patients with lymphomas are the main factors propelling the global market for Hodgkin’s lymphoma.

The Hodgkin’s lymphoma market scope comprises therapy as targeted therapy, chemotherapy, immunotherapy and others, which has increased the Hodgkin’s lymphoma market share. The global market for Hodgkin’s lymphoma is expanding as a result of factors including increasing research and development and their upcoming novel product approvals across countries are also creating a positive outlook for the Hodgkin’s lymphoma market growth.

Market Dynamics

The Rising Incidence and Mortality Rates Will Drive the Growth of the Hodgkin’s Lymphoma Market

One of the key drivers of the global Hodgkin's lymphoma market is the increasing prevalence of Hodgkin's lymphoma. According to cancer.net, there will be 8,830 Hodgkin lymphoma diagnoses in the US in 2023 (4,850 males and 3,980 females). Since the middle of the 2000s, there has been a 1% annual decline in the number of patients with this disease. In 2020, there will be 83,087 Hodgkin lymphoma diagnoses worldwide.

In 2023, it is predicted that this disease will cause 900 fatalities in the United States (540 deaths in males and 360 deaths in females). Since roughly 1975, the rate of survival has been increasing as a result of advancements in medical care.

Hodgkin lymphoma can affect both children and adults. In the US, two age categories are where it is most common. The first group consists of young adults, particularly those who are in their 20s. The second category includes those who are above 55. The usual diagnosis age is 39. Although the condition is rare in young children below the age of 5, it is the most prevalent malignancy detected in teenagers around the ages of 15 or 19.

Rising Research and Development and Novel Product Launches Creates Lucrative Opportunities for Manufacturers

Various research studies are being conducted by researchers for better treatment options for patients with Hodgkin’s lymphoma as immune checkpoint inhibitors are currently being studied as a single treatment, when combined with BV (Brentuximab vedotin) and in conjunction with chemotherapy, in addition to traditional BV and chemotherapy combos.

Furthermore, several advancements and initiatives have been started by the government and various other organizations. For instance, The goal of the Lymphoma Specialized Programs of Research Excellence (Lymphoma SPOREs) is to swiftly translate results from fundamental research into therapeutic settings. The Lymphoma SPOREs fund the creation of fresh immunotherapies, cutting-edge targeted treatments and innovative techniques for figuring out each patient's prognosis.

On November 10, 2022, ADCETRIS (brentuximab vedotin), in conjunction with doxorubicin, etoposide, vincristine, prednisone and cyclophosphamide, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients who are two years or older with high-risk classical Hodgkin lymphoma (cHL).

High Cost Of Treatment Will Hamper the Growth of the Market.

However, it is anticipated that the market will be hampered by the expensive nature of chemotherapy and the beginning of side effects from the treatment. For instance, it's possible for negative consequences including cardiovascular disease and secondary cancers including lymphoma, acute leukemia and solid tumors to manifest.

COVID-19 Impact Analysis

The COVID-19 epidemic and the worldwide lockdown have had an effect on the financial health of businesses in all industries. As a result, the U.S. Food and Drug Administration (FDA) released guidelines for the duration of the COVID-19 health emergency that include general considerations to assist sponsors and researchers, ensure trial participants' safety, follow good clinical practice (GCP) and reduce risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global Hodgkin’s lymphoma market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global Hodgkin’s lymphoma market growth over the forecast period.

Segment Analysis

The global Hodgkin’s lymphoma market is segmented based on therapy, type, end-user and region.

Nodular Sclerosis Hodgkin Lymphoma or NSCHL from Type Segment Accounts for 58.8% of Market Share Owing to High Incidence

Predominant nodular lymphocytes are a much more uncommon kind of lymphoma, this kind of Hodgkin's lymphoma includes lymphoma cells which are commonly referred to as ""popcorn cells"" due to their appearance. Dominant nodular lymphocytes when opposed to the more conventional form of the disease, Hodgkin's lymphoma is typically detected at its earliest stage and might need less intensive therapies.

The B-cells in lymph nodes in the neck or the chest region between the lungs are where nodular sclerosis typically begins. These B-cells develop into Reed-Sternberg cells, which are much larger, malignant cells. These cells aid in the diagnosis of Hodgkin lymphoma by medical professionals.

Sclerosis Nodular With 70% of cases being Hodgkin lymphoma or NSCHL, it is the most common kind of classical Hodgkin lymphoma (cHL). Lymph nodes that are affected have sclerosis-like fibrous structures. Similar rates of occurrence in men and women and very treatable. B symptoms are present in about 40% of cases.

Geographical Analysis

North America Accounted for Approximately 40.3% of the Market Share Owing to the Strong Presence of Major Players and the Advancements in Hodgkin’s Lymphomas

Manufacturers have chances to expand their operations in this region because of the rising demand for Hodgkin’s lymphoma for advancements in North America. The area has many producers and suppliers and its rapid economic development has raised industrial production of Hodgkin’s lymphoma, which has increased the demand.

There are many manufacturers and suppliers in North America and as a result of the region's rapid economic growth, industrial production has expanded, feeding the desire for the research and development of novel products.

The market will grow as new technology for research and development emerge. Rising technological developments, governmental approvals and the introduction of new products all contribute to growth. People are becoming more aware of novel products and therapies, leading to the expansion of the market in this region. These factors are responsible for the dominance of North America.

Competitive Landscape

The major global players in the Hodgkin’s lymphoma market include Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Bristol Myers Squibb, Seagen Inc., Actinium Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., AstraZeneca, Affimed GmbH and Incyte among others.

Why Purchase the Report?
• To visualize the global Hodgkin’s lymphoma market segmentation based on therapy, type, end-user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Hodgkin’s lymphoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global Hodgkin’s lymphoma market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023
• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies